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CC

:   colon cancer

CI

:   confidence interval

CIMP

:   CpG island methylator phenotype

CRC

:   colorectal cancer

DFS

:   disease‐free survival

dMMR

:   mismatch repair deficiency

EGFR

:   epidermal growth factor receptor

HR

:   hazard ratio

IHC

:   immunohistochemistry

MMR

:   mismatch repair

MSI‐H

:   microsatellite instability high

OS

:   overall survival

PD‐L1

:   programmed cell death‐ligand 1

pMMR

:   mismatch repair proficiency

sPD‐L1

:   PD‐L1 in stromal cells

TIL

:   tumor‐infiltrating lymphocyte

TMA

:   tissue microarray

TME

:   tumor microenvironment

tPD‐L1

:   PD‐L1 in tumor cells

VEGF

:   vascular endothelial growth factor

1. INTRODUCTION {#cas14495-sec-0001}
===============

Colorectal cancer is among the leading causes of cancer mortality worldwide.[^1^](#cas14495-bib-0001){ref-type="ref"} Despite improvements in prognosis due to treatment advances, including in surgery, chemotherapy, and molecular targeted therapy, the outcomes of CRC remain unsatisfactory. To improve survival, a more comprehensive understanding of the molecular biological mechanism underlying CRC is needed.

Prognosis differs according to tumor sidedness in CRC, with right‐sided CC (ie from the cecum to the splenic flexure) having worse survival than left‐sided CRC (ie from the splenic flexure to the rectum).[^2^](#cas14495-bib-0002){ref-type="ref"} This could be due to various biological and clinical differences including embryonic origin, vascular supply, and physiological function. Right‐sided CC is derived from the midgut. It is supplied by the superior mesenteric artery and frequently presents with *BRAF* mutation, MSI‐H, and CIMP. In contrast, left‐sided CRC is derived from the hindgut. It is supplied by the inferior mesenteric artery and frequently includes chromosomal instability.[^3^](#cas14495-bib-0003){ref-type="ref"} Accordingly, the efficacy of molecular targeted agents differs according to the tumor location. Anti‐VEGF mAbs, which prevent angiogenesis by binding VEGF‐A and/or B, are more effective in right‐sided CC, whereas anti‐EGFR mAb, which inhibits cell proliferation and survival by combining with EGFR, is more effective in left‐sided CRC.[^4^](#cas14495-bib-0004){ref-type="ref"}, [^5^](#cas14495-bib-0005){ref-type="ref"} Thus, tumor location should be considered when deciding the treatment plan.

The host immune state also plays a pivotal role in tumor progression. Several recent studies have reported that both the TME, including the TILs, macrophages, and immune‐checkpoint molecules, and clinicopathologic features influence cancer prognosis.[^6^](#cas14495-bib-0006){ref-type="ref"}, [^7^](#cas14495-bib-0007){ref-type="ref"}, [^8^](#cas14495-bib-0008){ref-type="ref"}, [^9^](#cas14495-bib-0009){ref-type="ref"}, [^10^](#cas14495-bib-0010){ref-type="ref"} In CRC, a high number of TILs are associated with better prognosis,[^6^](#cas14495-bib-0006){ref-type="ref"}, [^7^](#cas14495-bib-0007){ref-type="ref"} and the expression of some immune‐checkpoint molecules can be useful prognostic biomarkers.[^8^](#cas14495-bib-0008){ref-type="ref"}, [^9^](#cas14495-bib-0009){ref-type="ref"}, [^11^](#cas14495-bib-0011){ref-type="ref"}, [^12^](#cas14495-bib-0012){ref-type="ref"}, [^13^](#cas14495-bib-0013){ref-type="ref"} However, it remains unclear whether immunity differs according to the tumor location and which cells or molecules are involved in cancer prognosis.

DNA MMR is a system that recognizes and repairs erroneous DNA insertions and deletions. MMR deficiency results in the accumulation of insertion/deletion mutations in short repetitive sequence stretches called microsatellites, leading to the MSI phenotype. Some MSI‐induced mutations create several cancer neoantigens, which can be targeted by the immune cells. Thus, dMMR strongly influences tumor immunity.[^14^](#cas14495-bib-0014){ref-type="ref"}, [^15^](#cas14495-bib-0015){ref-type="ref"}, [^16^](#cas14495-bib-0016){ref-type="ref"} In general, dMMR is more frequent in right‐sided CC than in left‐sided CRC and is associated with better survival than pMMR.[^17^](#cas14495-bib-0017){ref-type="ref"}

Therefore, this study aimed to investigate the clinicopathologic differences according to the immunosurveillance pattern between right‐sided and left‐sided CRC, using IHC staining of MMR proteins to identify biomarkers and prognostic factors.

2. MATERIALS AND METHODS {#cas14495-sec-0002}
========================

2.1. Patients {#cas14495-sec-0003}
-------------

We reviewed formalin‐fixed, paraffin‐embedded tissue specimens from CRC patients who underwent surgical resection in Kurume University between 2007 and 2008. All patients had stage II or III disease as classified based on the 7th edition of the UICC TNM classification of malignant tumors. Clinical data were obtained from the patients' medical records. All patients were followed up until death or censorship. This study was approved by the Research Ethics Committee of Kurume University and was carried out according to the tenets of the Declaration of Helsinki.

2.2. Immunohistochemistry {#cas14495-sec-0004}
-------------------------

The primary Abs used for IHC were as follows: mouse monoclonal anti‐HLA class I ABC Ab (ab70328 \[EMR8‐5\]; Abcam), mouse monoclonal anti‐HLA DR + DP + DQ Ab (ab7856 \[CR3/43\]; Abcam), rabbit monoclonal anti‐PD‐L1 Ab (\#13684 \[E1L3N\]; Cell Signaling Technology), mouse monoclonal anti‐PD‐1 Ab (ab52587 \[NAT105\]; Abcam), mouse monoclonal anti‐CTLA‐4 Ab (UM800141 \[UMAB249\]; OriGene), mouse monoclonal anti‐CD3 Ab (M7254 \[F7.2.38\]; Dako), rabbit polyclonal anti‐CD4 Ab (790‐4423 \[SP35\]; Ventana), mouse monoclonal anti‐CD8 Ab (ab75129 \[C8/144B\]; Abcam), mouse monoclonal anti‐TIA‐1 Ab (IM2550 \[2G9A10F5\]; Beckman Coulter), mouse monoclonal anti‐T‐bet Ab (ab91109 \[4B10\]; Abcam), rabbit monoclonal anti‐GATA3 Ab (\#5852 \[D13C9\]; Cell Signaling Technology), mouse monoclonal anti‐RORγT Ab (MABF81 \[6F3.1\]; Merck Millipore), rabbit monoclonal anti‐Foxp3 Ab (ab99963 \[SP97\]; Abcam), and mouse monoclonal anti‐CD163 Ab (CD163‐L‐CE \[10D6\]; Leica), mouse monoclonal anti‐MSH2 Ab (M3639 \[FE11\]; Dako), rabbit monoclonal anti‐MSH6 Ab (M3646 \[EP49\]; Dako), rabbit monoclonal anti‐PMS2 Ab (M3647 \[EP51\]; Dako), and mouse monoclonal anti‐MLH1 Ab (M3640 \[ES05\]; Dako). We used the Dako ChemMate EnVision Kit system and a peroxidase/DAB kit for IHC. Some of them were stained in our previous study.[^10^](#cas14495-bib-0010){ref-type="ref"} Tissue microarray was constructed as reported in our previous study.[^10^](#cas14495-bib-0010){ref-type="ref"} Briefly, 1 tissue cylinder measuring 3.0 mm in diameter was punched from the center of the tumor using a tissue microarrayer.

2.3. Evaluation of IHC {#cas14495-sec-0005}
----------------------

Immunostaining was evaluated by 2 observers (HK and HM) blinded to the clinical data. The positive expression rate of HLA class I, HLA class II, and PD‐L1 on tumor cells was calculated. For HLA class I, positive cell membrane staining was considered positive expression. Expression of PD‐L1 was measured separately in both tumor and stromal cells. The total number of TILs with positive expression was counted. In every sample, 3 well‐stained hotspots were evaluated at ×400 magnification, which was equivalent to 0.19625 mm^2^, and the average of the 3 measurements was used for analyses. In evaluation of each protein expression, the comparison with internal positive or negative control was carried out in each TMA core. Some were counted in our previous study using ImageJ software.[^10^](#cas14495-bib-0010){ref-type="ref"} The numbers generated using automated counting by ImageJ were almost equal to the numbers obtained by manual visual counting.[^10^](#cas14495-bib-0010){ref-type="ref"} The median values were used as the cut‐off point in every analysis. Representative IHC images are shown in Figure [S1](#cas14495-sup-0001){ref-type="supplementary-material"}.

2.4. Definition of dMMR {#cas14495-sec-0006}
-----------------------

The MMR protein content was evaluated for the absence or presence of the following 4 MMR proteins: MSH2, MSH6, PMS2, and MLH1. Tumors showing total absence of nuclear staining in at least 1 of the 4 MMR proteins were defined as dMMR. The expression of MMR proteins in the normal epithelium and lymphocytes was used as the positive internal control for all cases. Four MMR deficiency patterns were assessed: (i) dMLH1/dPMS2; (ii) dMSH2/dMSH6; (iii) dMSH6; and (iv) dPMS2.

2.5. Statistical analysis {#cas14495-sec-0007}
-------------------------

The clinicopathologic characteristics were compared between right‐ and left‐sided CRC using the χ^2^ test for categorical variables and the Wilcoxon rank‐sum test for continuous variables. Survival curves were created using the Kaplan‐Meier method and compared using log‐rank test. Disease‐free survival was defined as the time from surgery to recurrence or death; OS was defined as the time from surgery to death. The Cox proportional hazards model was used for uni‐ and multivariate analyses. All statistical analyses were undertaken using JMP version 13 software (SAS Institute, Cary, NC, USA), and *P* \< .05 was considered to indicate statistical significance.

3. RESULTS {#cas14495-sec-0008}
==========

3.1. Comparison of clinicopathologic features according to tumor location {#cas14495-sec-0009}
-------------------------------------------------------------------------

A total of 117 cases were included in the analyses; of these, 30 were right‐sided CC, and 87 were left‐sided CRC. The clinicopathologic features between the 2 groups are summarized in Table [S1](#cas14495-sup-0011){ref-type="supplementary-material"}. There were more elderly patients in the right‐sided CC group (*P* = .0360). The number of patients with positive lymph node involvement was significantly lower in the right‐sided group than in the left‐sided group (7 \[23%\] vs. 44 \[51%\], *P* = .0078). Moreover, dMMR was significantly more frequent in the right‐sided group (20% vs. 5%, *P* = .0157). Other patient characteristics were not significantly different between the 2 groups.

3.2. Relationship between tumor location and IHC staining results {#cas14495-sec-0010}
-----------------------------------------------------------------

A comparison of each IHC staining result between the 2 groups is shown in Figure [S2](#cas14495-sup-0002){ref-type="supplementary-material"}. There were more biomarkers with positive expression in left‐sided CRC. The median HLA class I expression rate was significantly different between right‐ and left‐sided CRC (32% vs 77%, *P* = .0011). The CD4, RORγT, and CD163 infiltration was significantly more pronounced in left‐sided CRC (*P* = .0075, *P* = .0448, and *P* = .0050, respectively).

3.3. Comparison of DFS and OS curves {#cas14495-sec-0011}
------------------------------------

The comparison of DFS according to tumor sidedness is shown in Figure [1](#cas14495-fig-0001){ref-type="fig"}. In right‐sided CC, low HLA class I (*P* = .0060), high PD‐1 (*P* = .0190), high CD3 (*P* = .0099), high CD8 (*P* = .0151), high TIA‐1 (*P* = .0140), and high Foxp3 expression (*P* = .0190) were associated with significantly better DFS. In left‐sided CRC, only high sPD‐L1 expression (*P* = .0335) was associated with better DFS.

![Kaplan‐Meier curves of disease‐free survival (DFS) according to the location of colorectal tumor based on the expression of HLA class I, programmed cell death‐ligand 1 on stromal cells (sPD‐L1), programmed cell death‐1 (PD‐1), CD3, CD8, TIA‐1, and Foxp3. Median values were used as the cut‐off point](CAS-111-3032-g001){#cas14495-fig-0001}

A comparison of OS according to tumor sidedness is shown in Figure [2](#cas14495-fig-0002){ref-type="fig"}. Low HLA class I expression was associated with better OS in the right‐sided CC group, but there was no significant difference in OS between those with high and with low HLA class I expression (*P* = .0689). High sPD‐L1 (*P* = .0053) and high CD3 expression (*P* = .0305) were correlated with better OS in the left‐sided CRC group.

![Kaplan‐Meier curves of overall survival (OS) according to location of colorectal tumor based on the expression of HLA class I, programmed cell death‐ligand 1 on stromal cells (sPD‐L1), and CD3. Median values were used as the cut‐off point](CAS-111-3032-g002){#cas14495-fig-0002}

Kaplan‐Meier curves of DFS and OS in other biomarkers are shown in Figures [\[Link\]](#cas14495-sup-0003){ref-type="supplementary-material"}, [\[Link\]](#cas14495-sup-0004){ref-type="supplementary-material"}, [\[Link\]](#cas14495-sup-0005){ref-type="supplementary-material"}.

3.4. Comparison of clinicopathologic features and survival between tumor location in MMR proficiency {#cas14495-sec-0012}
----------------------------------------------------------------------------------------------------

The clinicopathologic features between the 2 groups in MMR proficiency are summarized in Table [1](#cas14495-tbl-0001){ref-type="table"}. There were more elderly patients in the right‐sided CC group (*P* = .0145). The number of patients with positive lymph node involvement was significantly lower in the right‐sided group than in the left‐sided group (7 \[29%\] vs. 43 \[52%\], *P* = .0470). There were no other significant differences in patient characteristics between the 2 groups. Neither DFS nor OS was significantly different between the 2 groups (Figure [S6](#cas14495-sup-0006){ref-type="supplementary-material"}).

###### 

Relationship between tumor location and clinicopathologic characteristics of DNA mismatch repair proficient (pMMR) colorectal cancer patients

  pMMR                                               
  ------------------------- ---- ---- ---- ---- ---- -----------------------------------------------
  Sex                                                
  Male                      15   63   56   67   71   .0652
  Female                    9    38   27   33   36   
  Age (y), median (range)                            
  ≤70                       8    33   51   61   59   .0145[\*](#cas14495-note-0010){ref-type="fn"}
  \>70                      16   67   32   39   48   
  Tumor depth                                        
  T1‐2                      2    8    7    8    9    .9875
  T3‐4                      22   92   76   92   98   
  Lymph node metastasis                              
  Negative                  17   71   40   48   57   .0470[\*](#cas14495-note-0010){ref-type="fn"}
  Positive                  7    29   43   52   50   
  Tumor differentiation                              
  Well/moderate             21   88   73   88   94   .9526
  Others                    3    12   10   12   13   
  Lymphatic invasion                                 
  Negative                  12   50   35   42   47   .4971
  Positive                  12   50   48   58   60   
  Venous invasion                                    
  Negative                  5    21   20   24   29   .7370
  Positive                  19   79   63   76   88   
  Perineural invasion                                
  Negative                  20   83   64   77   84   .5039
  Positive                  4    17   19   23   23   
  Adjuvant chemotherapy                              
  No                        17   71   49   59   66   .2885
  Yes                       7    29   34   41   41   
  Recurrence                                         
  No                        8    33   23   28   33   .5963
  Yes                       16   67   60   72   84   

*P* \< .05

John Wiley & Sons, Ltd

3.5. Relationship between tumor location and IHC staining results in pMMR {#cas14495-sec-0013}
-------------------------------------------------------------------------

A comparison of each IHC staining result between the 2 groups excluding dMMR is shown in Figure [3](#cas14495-fig-0003){ref-type="fig"}. There were more biomarkers with positive expression in left‐sided CRC, even in pMMR. The median expression of HLA class I and HLA class II was significantly different between right‐ and left‐sided CRC (39% vs. 77%, *P* = .0208 and 0.5% vs. 5%, *P* = .0498, respectively). The PD‐1, CD4, CD8, and CD163 infiltration was significantly more pronounced in left‐sided CRC (*P* = .0296, *P* = .0017, *P* = .0129, and *P* = .0025, respectively).

![Molecular expression rate/number in right‐ and left‐sided colorectal tumors in DNA mismatch repair proficiency. Numbers above each plot represent the median and interquartile range. HPF, high power field; PD‐1, programmed cell death‐1; sPD‐L1, programmed cell death‐ligand 1 in stromal cells; tPD‐L1, programmed cell death‐ligand 1 in tumor cells](CAS-111-3032-g003){#cas14495-fig-0003}

3.6. Comparison of DFS and OS curves between 2 groups in pMMR {#cas14495-sec-0014}
-------------------------------------------------------------

A comparison of DFS between the 2 groups excluding dMMR is shown in Figure [4](#cas14495-fig-0004){ref-type="fig"}. In right‐sided CC, high expression of Foxp3 (*P* = .0055) and TIA‐1 (*P* = .0396) was associated with significantly better DFS. Patients with high CD8 (*P* = .0808) and CD3 (.0863) expression tended to have better DFS. In left‐sided CRC, only high sPD‐L1 expression (*P* = .0426) was associated with better DFS.

![Kaplan‐Meier curves of disease‐free survival (DFS) according to location of colorectal tumor excluding DNA mismatch repair deficiency based on the expression of HLA class I, HLA class II, programmed cell death‐ligand 1 on stromal cells (sPD‐L1), CD3, CD8, TIA‐1, and Foxp3. Median values were used as the cut‐off point](CAS-111-3032-g004){#cas14495-fig-0004}

A comparison of OS between the 2 groups excluding dMMR is shown in Figure [5](#cas14495-fig-0005){ref-type="fig"}. In right‐sided CC, high expression of CTLA‐4 (*P* = .0496) and Foxp3 (*P* = .0479) was associated with better OS. In left‐sided CRC, high expression of sPD‐L1 (*P* = .0204) and CD3 (*P* = .0486) correlated with better OS.

![Kaplan‐Meier curves of overall survival (OS) according to location of colorectal tumor excluding DNA mismatch repair deficiency based on the expression of programmed cell death‐ligand 1 on stromal cells (sPD‐L1), CTLA‐4, CD3, and Foxp3. Median values were adopted as the cut‐off point](CAS-111-3032-g005){#cas14495-fig-0005}

Kaplan‐Meier curves of DFS and OS according to the other biomarkers are shown in Figures [\[Link\]](#cas14495-sup-0007){ref-type="supplementary-material"}, [\[Link\]](#cas14495-sup-0008){ref-type="supplementary-material"}, [\[Link\]](#cas14495-sup-0009){ref-type="supplementary-material"}.

3.7. Univariate and multivariate analyses for DFS and OS in pMMR {#cas14495-sec-0015}
----------------------------------------------------------------

The results of univariate and multivariate analyses of DFS and OS in pMMR are shown in Tables [2](#cas14495-tbl-0002){ref-type="table"} and [3](#cas14495-tbl-0003){ref-type="table"}. Univariate analysis of DFS in right‐sided CC excluding dMMR showed that the prognostic factors were TIA‐1 (HR, 4.5348; 95% CI, 1.0431‐30.969; *P* = .0435) and Foxp3 (HR, 10.642; 95% CI, 1.8744‐199.65; *P* = .0052) expression. However, only Foxp3 expression (HR, 7.6445; 95% CI, 1.2091‐150.35; *P* = .0284) remained significant on multivariate analysis. For OS, CTLA‐4 expression (HR, 4.2365; 95% CI, 1.0184‐28.519; *P* = .0470) and Foxp3 expression (HR, 4.2911; 95% CI, 1.0283‐28.943; *P* = .0454) were significant factors on univariate analysis.

###### 

Uni‐ and multivariate analyses of disease‐free survival (DFS) in each tumor location in DNA mismatch repair proficiency

                                               DFS                                                                                               
  -------------------------------------------- ------------------------ ----------------------------------------------- ------------------------ ------------------------------------------------
  Right‐sided                                                                                                                                    
  Sex (M vs F)                                 0.6220 (0.1462‐2.6455)   .5058                                           ---                      ---
  Age (≤70 vs 70\<)                            2.5263 (0.5955‐10.718)   .1987                                           ---                      ---
  Tumor depth (T1‐2 vs T3‐4)                   1.4230 (0.0760‐8.0387)   .7525                                           ---                      ---
  Lymph node metastasis (− vs +)               0.5232 (0.1279‐2.5580)   .3924                                           ---                      ---
  Tumor differentiation (well/mod vs others)   0.3386 (0.0772‐2.3240)   .2318                                           ---                      ---
  Lymphatic invasion (− vs +)                  0.5531 (0.1132‐2.2516)   .4080                                           ---                      ---
  Venous invasion (− vs +)                     1.9345 (0.3957‐7.9113)   .3839                                           ---                      ---
  Perineural invasion (− vs +)                 not estimated            .1240                                           ---                      ---
  HLA classI (low vs high)                     0.4950 (0.1012‐2.0265)   .3279                                           ---                      ---
  HLA classII (low vs high)                    0.5922 (0.1214‐2.4163)   .4663                                           ---                      ---
  tPD‐L1 (low vs high)                         1.0683 (0.2509‐4.5490)   .9260                                           ---                      ---
  sPD‐L1 (low vs high)                         2.1146 (0.5135‐10.407)   .2993                                           ---                      ---
  PD‐1 (low vs high)                           2.9767 (0.6845‐20.334)   .1516                                           ---                      ---
  CTLA‐4 (low vs high)                         0.9789 (0.2312‐4.1445)   .9760                                           ---                      ---
  CD3 (low vs high)                            3.6488 (0.8367‐24.968)   .0868                                           ---                      ---
  CD4 (low vs high)                            2.1619 (0.5256‐10.629)   .2848                                           ---                      ---
  CD8 (low vs high)                            3.7213 (0.8541‐25.451)   .0817                                           ---                      ---
  TIA‐1 (low vs high)                          4.5348 (1.0431‐30.969)   .0435[\*](#cas14495-note-0002){ref-type="fn"}   2.3141 (0.4948‐16.784)   0.3010
  T‐bet (low vs high)                          0.6873 (0.1409‐2.8030)   .6032                                           ---                      ---
  GATA3 (low vs high)                          3.4926 (0.7988‐23.938)   .0992                                           ---                      ---
  Foxp3 (low vs high)                          10.642 (1.8744‐199.65)   .0052[\*](#cas14495-note-0002){ref-type="fn"}   7.6445 (1.2091‐150.35)   0.0284[\*](#cas14495-note-0002){ref-type="fn"}
  RorγT (low vs high)                          1.1726 (0.2772‐4.9607)   .8220                                           ---                      ---
  CD163 (low vs high)                          1.7702 (0.4341‐8.6335)   .4264                                           ---                      ---
  Left‐sided                                                                                                                                     
  Sex (M vs F)                                 1.3592 (0.5645‐3.7677)   .5085                                           ---                      ---
  Age (≤70 vs 70\<)                            1.3729 (0.5858‐3.5732)   .4763                                           ---                      ---
  Tumor depth (T1‐2 vs T3‐4)                   0.3869 (0.0216‐1.8445)   .2809                                           ---                      ---
  Lymph node metastasis (N− vs N+)             0.4422 (0.1778‐1.0194)   .0556                                           ---                      ---
  Tumor differentiation (well/mod vs others)   0.1198 (0.0498‐0.3190)   .0001[\*](#cas14495-note-0002){ref-type="fn"}   0.0975 (0.0289‐0.3185)   0.0002[\*](#cas14495-note-0002){ref-type="fn"}
  Lymphatic invasion (− vs +)                  0.3804 (0.1370‐0.9178)   .0308[\*](#cas14495-note-0002){ref-type="fn"}   0.5718 (0.1832‐1.5692)   0.2860
  Venous invasion (− vs +)                     0.2495 (0.0399‐0.851)    .0237[\*](#cas14495-note-0002){ref-type="fn"}   0.1751 (0.0234‐0.7904)   0.0213[\*](#cas14495-note-0002){ref-type="fn"}
  Perineural invasion (− vs +)                 0.3462 (0.1510‐0.8357)   .0197[\*](#cas14495-note-0002){ref-type="fn"}   0.6546 (0.2561‐1.7916)   0.3959
  HLA classI (low vs high)                     1.5318 (0.6718‐3.6781)   .3127                                           ---                      ---
  HLA classII (low vs high)                    1.6024 (0.7023‐3.8497)   .2642                                           ---                      ---
  tPD‐L1 (low vs high)                         1.2984 (0.5694‐3.1178)   .5379                                           ---                      ---
  sPD‐L1 (low vs high)                         2.3519 (1.0210‐5.8450)   .0445[\*](#cas14495-note-0002){ref-type="fn"}   1.9256 (0.7099‐5.2939)   0.1952
  PD‐1 (low vs high)                           1.1986 (0.5253‐2.7622)   .6642                                           ---                      ---
  CTLA‐4 (low vs high)                         1.6485 (0.7246‐3.8642)   .2325                                           ---                      ---
  CD3 (low vs high)                            0.9694 (0.4205‐2.2126)   .9406                                           ---                      ---
  CD4 (low vs high)                            1.3970 (0.6141‐3.2749)   .4248                                           ---                      ---
  CD8 (low vs high)                            1.6932 (0.7425‐4.0657)   .2117                                           ---                      ---
  TIA‐1 (low vs high)                          1.5849 (0.6950‐3.8055)   .2753                                           ---                      ---
  T‐bet (low vs high)                          0.7746 (0.3306‐1.7611)   .5421                                           ---                      ---
  GATA3 (low vs high)                          1.9569 (0.8498‐4.8618)   .1159                                           ---                      ---
  Foxp3 (low vs high)                          1.0084 (0.4373‐2.3027)   .9841                                           ---                      ---
  RorγT (low vs high)                          1.6612 (0.7281‐3.9908)   .2292                                           ---                      ---
  CD163 (low vs high)                          1.3319 (0.5856‐3.1216)   .4940                                           ---                      ---

Abbreviations: CI, confidence interval; DFS, disease ‐ free survival; F, female; HR, hazard ratio; M, male; mod, moderate; PD‐1, programmed cell death‐1; sPD‐L1, programmed cell death‐ligand 1 in stromal cells; tPD‐L1, programmed cell death‐ligand 1 in tumor cells.

*P* \< .05.

John Wiley & Sons, Ltd

###### 

Uni‐ and multivariate analyses of overall survival (OS) in each tumor location in DNA mismatch repair proficiency

                                               OS                                                                                                
  -------------------------------------------- ------------------------ ----------------------------------------------- ------------------------ -----------------------------------------------
  Right‐sided                                                                                                                                    
  Sex (M vs F)                                 1.4708 (0.3868‐6.9864)   .5792                                           ---                      ---
  Age, y (≤70 vs 70\<)                         0.5468 (0.0792‐2.4145)   .4446                                           ---                      ---
  Tumor depth (T1‐2 vs T3‐4)                   Not estimated            .1556                                           ---                      ---
  Lymph node metastasis (− vs +)               0.5803 (0.1414‐2.8439)   .4705                                           ---                      ---
  Tumor differentiation (well/mod vs others)   0.9602 (0.1691‐18.012)   .9700                                           ---                      ---
  Lymphatic invasion (− vs +)                  1.8034 (0.4408‐8.8175)   .4125                                           ---                      ---
  Venous invasion (− vs +)                     0.4018 (0.0215‐2.2668)   .3418                                           ---                      ---
  Perineural invasion (− vs +)                 0.3743 (0.0858‐2.5630)   .2726                                           ---                      ---
  HLA class I (low vs high)                    0.7919 (0.1958‐2.9964)   .7275                                           ---                      ---
  HLA class II (low vs high)                   1.3584 (0.3589‐5.4955)   .6471                                           ---                      ---
  tPD‐L1 (low vs high)                         0.8374 (0.2068‐3.1734)   .7913                                           ---                      ---
  sPD‐L1 (low vs high)                         1.3198 (0.3102‐5.6158)   .6966                                           ---                      ---
  PD‐1 (low vs high)                           1.4554 (0.3550‐7.1293)   .6043                                           ---                      ---
  CTLA‐4 (low vs high)                         4.2365 (1.0184‐28.519)   .0470[\*](#cas14495-note-0012){ref-type="fn"}   3.4053 (0.7683‐23.727)   .1105
  CD3 (low vs high)                            1.1376 (0.2685‐4.8206)   .8556                                           ---                      ---
  CD4 (low vs high)                            1.3014 (0.3060‐5.5363)   .7112                                           ---                      ---
  CD8 (low vs high)                            1.0485 (0.2473‐4.4458)   .9467                                           ---                      ---
  TIA‐1 (low vs high)                          1.5232 (0.4013‐6.1790)   .5303                                           ---                      ---
  T‐bet (low vs high)                          1.7270 (0.4546‐7.0084)   .4155                                           ---                      ---
  GATA3 (low vs high)                          3.6282 (0.8704‐24.463)   .0787                                           ---                      ---
  Foxp3 (low vs high)                          4.2911 (1.0283‐28.943)   .0454[\*](#cas14495-note-0012){ref-type="fn"}   3.4420 (0.7787‐23.947)   .1066
  RorγT (low vs high)                          1.5860 (0.4180‐6.4309)   .4914                                           ---                      ---
  CD163 (low vs high)                          1.4638 (0.3854‐5.9416)   .5701                                           ---                      ---
  Left‐sided                                                                                                                                     
  Sex (M vs F)                                 0.8082 (0.3679‐1.9001)   .6104                                           ---                      ---
  Age, y (≤70 vs 70\<)                         0.5784 (0.2648‐1.2825)   .1739                                           ---                      ---
  Tumor depth (T1‐2 vs T3‐4)                   0.3058 (0.0171‐1.4537)   .1614                                           ---                      ---
  Lymph node metastasis (N− vs N+)             0.3339 (0.1303‐0.7605)   .0082[\*](#cas14495-note-0012){ref-type="fn"}   0.6190 (0.2189‐1.6265)   .3344
  Tumor differentiation (well/mod vs others)   0.1891 (0.0800‐0.4964)   .0014[\*](#cas14495-note-0012){ref-type="fn"}   0.2895 (0.1018‐0.8644)   .0274[\*](#cas14495-note-0012){ref-type="fn"}
  Lymphatic invasion (− vs +)                  0.2622 (0.0873‐0.6459)   .0027[\*](#cas14495-note-0012){ref-type="fn"}   0.3336 (0.1037‐0.9127)   .0318[\*](#cas14495-note-0012){ref-type="fn"}
  Venous invasion (− vs +)                     0.3366 (0.0796‐0.9727)   .0437[\*](#cas14495-note-0012){ref-type="fn"}   0.3776 (0.0843‐1.2222)   .1090
  Perineural invasion (− vs +)                 0.3405 (0.1538‐0.7864)   .0129[\*](#cas14495-note-0012){ref-type="fn"}   0.7228 (0.2996‐1.7867)   .4742
  HLA class I (low vs high)                    1.6634 (0.7644‐3.8001)   .2011                                           ---                      ---
  HLA class II (low vs high)                   1.1777 (0.5421‐2.5977)   .6782                                           ---                      ---
  tPD‐L1 (low vs high)                         0.5936 (0.2626‐1.3081)   .1949                                           ---                      ---
  sPD‐L1 (low vs high)                         2.5843 (1.1600‐6.3016)   .0196[\*](#cas14495-note-0012){ref-type="fn"}   1.7512 (0.6893‐4.6548)   .2393
  PD‐1 (low vs high)                           2.1281 (0.9656‐5.0206)   .0612                                           ---                      ---
  CTLA‐4 (low vs high)                         1.7347 (0.7948‐3.9707)   .1676                                           ---                      ---
  CD3 (low vs high)                            2.2688 (1.0144‐5.5475)   .0460[\*](#cas14495-note-0012){ref-type="fn"}   2.3560 (0.9905‐6.0541)   .0526
  CD4 (low vs high)                            1.5236 (0.6964‐3.4939)   .2941                                           ---                      ---
  CD8 (low vs high)                            1.6338 (0.7483‐3.7475)   .2197                                           ---                      ---
  TIA‐1 (low vs high)                          1.1064 (0.5106‐2.4350)   .7970                                           ---                      ---
  T‐bet (low vs high)                          1.0622 (0.4836‐2.3383)   .8792                                           ---                      ---
  GATA3 (low vs high)                          1.0641 (0.4911‐2.3413)   .8745                                           ---                      ---
  Foxp3 (low vs high)                          1.4531 (0.6679‐3.2590)   .3464                                           ---                      ---
  RorγT (low vs high)                          1.5666 (0.7171‐3.5898)   .2623                                           ---                      ---
  CD163 (low vs high)                          1.2735 (0.5856‐2.8553)   .5428                                           ---                      ---

Abbreviations: CI, confidence interval; F, female; HR, hazard ratio; M, male; mod, moderate; PD‐1, programmed cell death‐1; sPD‐L1, programmed cell death‐ligand 1 in stromal cells; tPD‐L1, programmed cell death‐ligand 1 in tumor cells.

*P* \< .05
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Univariate analysis of DFS in left‐sided CRC showed that tumor differentiation (HR, 0.1198; 95% CI, 0.0498‐0.3190; *P* = .0001), lymphatic invasion (HR, 0.3804; 95% CI, 0.1370‐0.9178; *P* = .0308), venous invasion (HR, 0.2495; 95% CI, 0.0399‐0.8510; *P* = .0237), perineural invasion (HR, 0.3462; 95% CI, 0.1510‐0.8357; *P* = .0197), and sPD‐L1 expression (HR, 2.3519; 95% CI, 1.0210‐5.8450; *P* = .0445) were prognostic factors. However, only tumor differentiation (HR, 0.0975; 95% CI, 0.0289‐0.3185; *P* = .0002) and venous invasion (HR, 0.1751; 95% CI, 0.0234‐0.7904; *P* = .0213) remained significant on multivariate analysis. For OS, lymph node metastasis (HR, 0.3339; 95% CI, 0.1303‐0.7605; *P* = .0082), tumor differentiation (HR, 0.1891; 95% CI, 0.0800‐0.4964; *P* = .0014), lymphatic invasion (HR, 0.2622; 95% CI, 0.0873‐0.6459; *P* = .0027), venous invasion (HR, 0.3366; 95% CI, 0.0796‐0.9727; *P* = .0437), perineural invasion (HR, 0.3405; 95% CI, 0.1538‐0.7864; *P* = .0129), sPD‐L1 expression (HR, 2.5843; 95% CI, 1.1600‐6.3016; *P* = .0196), and CD3 expression (HR, 2.2688; 95% CI, 1.0144‐5.5475; *P* = .0460) were the significant factors of prognosis on univariate analysis. On multivariate analysis, only tumor differentiation (HR, 0.2895; 95% CI, 0.1018‐0.8644; *P* = .0274) and lymphatic invasion (HR, 0.3336; 95% CI, 0.1037‐0.9127; *P* = .0318) remained significant.

4. DISCUSSION {#cas14495-sec-0016}
=============

The present study investigated the differences in immunosurveillance pattern between right‐sided and left‐sided CRC and analyzed their association with clinicopathologic features, including clinical outcomes. The results showed that the immunosurveillance pattern differed between right‐sided and left‐sided CRC. We found lower HLA class I expression in right‐sided CC and higher CD4, RORγT, and CD163 expression in left‐sided CRC (Figure [3](#cas14495-fig-0003){ref-type="fig"}). Log‐rank test showed that low HLA class I, high PD‐1, high CD3, high CD8, high TIA‐1, and high Foxp3 expression were associated with better DFS in right‐sided CC, whereas only high sPD‐L1 and CD3 expression were associated with better DFS in left‐sided CRC. Additionally, analyses excluding dMMR showed a significant difference in the immunosurveillance pattern according to tumor sidedness even in pMMR. Right‐sided CC presented lower HLA class I, HLA class II, PD‐1, CD4, CD8, and CD163 expression than left‐sided CRC. Log‐rank test showed that high expression of CD3, CD8, TIA‐1, and Foxp3 was associated with better DFS in right‐sided CC, whereas high sPD‐L1 and CD3 expression was associated with better DFS in left‐sided CRC. Multivariate analysis of DFS in right‐sided CC excluding dMMR showed that high Foxp3 expression was the only prognostic factor. Despite the more profound immune cell infiltration in left‐sided CRC, immunity had a stronger prognostic influence in right‐sided CC.

MMR deficiency markedly affects tumor immunity and some dMMR‐induced mutations create cancer neoantigens that can be targeted by the immune cells. MMR deficiency is more common in right‐sided than in left‐sided CRC.[^17^](#cas14495-bib-0017){ref-type="ref"} We analyzed the 2 groups excluding dMMR and found differences even in pMMR. This suggests that tumor immunity is not only affected by the genetic background but also by the tumor location itself. Other methylator phenotypes, such as CIMP, might influence these differences. However, Takahashi et al reported no difference in the frequency of DNA methylation status between right‐ and left‐sided CRC in the microsatellite stable group.[^18^](#cas14495-bib-0018){ref-type="ref"} Additionally, CIMP‐H frequently occurs simultaneously with MSI‐H.[^19^](#cas14495-bib-0019){ref-type="ref"}

We also found that high expression of the TILs (CD3, CD8, TIA‐1, and Foxp3) indicates better prognosis in right‐sided CC, which is partly in line with the results of some studies.[^20^](#cas14495-bib-0020){ref-type="ref"}, [^21^](#cas14495-bib-0021){ref-type="ref"}, [^22^](#cas14495-bib-0022){ref-type="ref"} Berntsson et al and Zhang et al reported that a high number of PD‐1, CD3, and/or CD8 is related to better prognosis in right‐sided CC. High Foxp3 expression is generally associated with poor prognosis in various carcinomas.[^23^](#cas14495-bib-0023){ref-type="ref"}, [^24^](#cas14495-bib-0024){ref-type="ref"} However, some studies reported that high number of Foxp3 expression is associated with favorable prognosis in CRC.[^20^](#cas14495-bib-0020){ref-type="ref"}, [^25^](#cas14495-bib-0025){ref-type="ref"}, [^26^](#cas14495-bib-0026){ref-type="ref"} The reason for the association of high Foxp3 expression with good prognosis only in right‐sided remains unknown.

High sPD‐L1 expression indicates good prognosis in left‐sided CRC, but the influence of PD‐1/PD‐L1 expression in CRC prognosis remains controversial.[^21^](#cas14495-bib-0021){ref-type="ref"}, [^27^](#cas14495-bib-0027){ref-type="ref"}, [^28^](#cas14495-bib-0028){ref-type="ref"}, [^29^](#cas14495-bib-0029){ref-type="ref"}, [^30^](#cas14495-bib-0030){ref-type="ref"}, [^31^](#cas14495-bib-0031){ref-type="ref"} Keir et al suggested that PD‐L1 might be upregulated in activated macrophages and dendritic cells.[^32^](#cas14495-bib-0032){ref-type="ref"}, [^33^](#cas14495-bib-0033){ref-type="ref"} Spranger et al also reported that interferon‐γ secreted by the activated lymphocytes and macrophages induces PD‐L1 upregulation on the cell surface.[^34^](#cas14495-bib-0034){ref-type="ref"} Thus, high sPD‐L1 expression could reflect immune activation.

Snyder et al[^35^](#cas14495-bib-0035){ref-type="ref"} reported that the efficacy of immune checkpoint inhibitors in melanoma differs according to the number of infiltrative CD8 in the tumor adjacent tissue. In the present study, the immune environment varied according to the tumor location, even when excluding dMMR. This shows that the impact of immune checkpoint inhibitors or any other immune therapies for CRC could vary with the tumor's anatomical site. Therefore, the tumor location should be considered during immune therapy.

The IHC analyses in this study were undertaken using TMA. Although the validity of IHC analysis of TMA might be controversial, there have been several IHC studies using TMA since it was first introduced.[^36^](#cas14495-bib-0036){ref-type="ref"}, [^37^](#cas14495-bib-0037){ref-type="ref"} In the present study, we evaluated some biomarkers through whole‐section staining in 10 cases and confirmed the significant correlation between TMA and whole‐section staining (Figure [S10](#cas14495-sup-0010){ref-type="supplementary-material"}). The results of the present study were concordant with the other previous reports that high number of TILs showed better survival, especially in right‐sided tumors.[^20^](#cas14495-bib-0020){ref-type="ref"}, [^21^](#cas14495-bib-0021){ref-type="ref"}, [^22^](#cas14495-bib-0022){ref-type="ref"} The use of IHC analyses through TMA in the present study was considered to be validated.

This study has some limitations. First, there is a potential risk of selection bias due to the single‐center, retrospective study design. Our findings should be validated in a larger cohort study. Second, other immune‐related proteins should have been considered for a more comprehensive analyses of TME. Finally, only proteins were evaluated in the present study. mRNA and gene analyses, including *CIMP* and *BRAF*, are needed to validate our results.

In conclusion, the immunosurveillance pattern and its influence on the clinical outcome differs between right‐sided and left‐sided CRC, even in pMMR. Therefore, planning the treatment according to the tumor location could improve the prognosis of CRC patients.
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